Single Nucleotide Polymorphisms (SNPs) are the most common genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. SNP genotyping is the process of analyzing these genetic variations within populations or between individuals. This technique is essential in identifying disease associations, understanding genetic predispositions, and enabling personalized medicine.
SNP genotyping involves various advanced technologies such as PCR-based methods, microarrays, and next-generation sequencing (NGS). Each technology offers unique advantages, allowing researchers and clinicians to explore genetic diversity at an unprecedented scale and depth. The insights gained from SNP genotyping drive advancements in pharmacogenomics, crop improvement, and evolutionary biology.
The global Single Nucleotide Polymorphism (SNP) genotyping market is experiencing significant growth. The market is expected to grow from $32.0 billion in 2024 and is projected to reach $85.5 billion by the end of 2029. This growth corresponds to a robust compound annual growth rate (CAGR) of 21.7% during the forecast period from 2024 to 2029. The expansion is driven by increasing demand for personalized medicine, the rise of genetic testing, and the integration of AI (Artificial Intelligence) and bioinformatics in genomics research.